A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

Launched by ABBVIE · May 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying new treatments for people with moderately to severely active rheumatoid arthritis (RA), a condition that causes joint pain, stiffness, and swelling. The trial will test three different therapies: one is lutikizumab, another is ravagalimab, and the last one combines both of these treatments. Some participants will receive a placebo, which looks like the medication but doesn't contain any active ingredients. The goal is to see how well these treatments work and if they are safe for people who have already tried and not responded well to other RA medications.

To be eligible for this trial, participants must have been treated with certain RA medications for at least three months but still have active symptoms. They also need to be on a stable dose of methotrexate, which is a common RA medication. Participants will need to attend regular visits at a hospital or clinic for assessments, blood tests, and to monitor any side effects. It’s important to know that participating in this trial may involve more visits and treatments compared to standard care. The study is not yet recruiting, but it aims to include about 180 participants from around the world.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • At any time prior to the Screening Visit, participant must have been treated for \> or = 3 months with at least 1 b/tsDMARD therapy but continued to exhibit active RA, or had to discontinue due to intolerability or toxicity, irrespective of treatment duration. The maximum cap for prior use of b/tsDMARD is 2.
• • Participant must be on a stable dose of methotrexate (MTX)
• Exclusion Criteria:
• • Participant is taking nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen/paracetamol, low-potency opioids (tramadol, codeine, hydrocodone, alone or in combination with acetaminophen), oral corticosteroids (equivalent to ≤ 10 mg/day of prednisone), or inhaled corticosteroids for stable medical conditions unless they have been on stable doses for ≥ 1 week prior to Baseline Visit.
• • History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than rheumatoid arthritis.